drugset / Trial / NCT05673460
A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of nemtabrutinib in Japanese participants with mature B-cell neoplasms.
Timeline
- Start
- 2023-02-13
- Primary completion
- 2025-04-28
- Completion
- 2025-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemtabrutinib | Other / unclassified | 45 mg | Oral |
| Subject | Nemtabrutinib | Other / unclassified | 65 mg | Oral |